About Yecuris
Yecuris is a company based in Tualatin (United States) founded in 2007 was acquired by Janiver Labs in January 2024. Yecuris has raised $1.25 million across 5 funding rounds from investors including HHS and Janiver Labs. The company has 26 employees as of December 31, 2022. Yecuris offers products and services including FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services. Yecuris operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.
- Headquarter Tualatin, United States
- Employees 26 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Yecuris Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.25 M (USD)
in 5 rounds
-
Latest Funding Round
$453.28 K (USD), Grant
Mar 19, 2012
-
Investors
HHS
& 1 more
-
Employee Count
26
as on Dec 31, 2022
-
Acquired by
Janiver Labs
(Jan 30, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Yecuris
Yecuris offers a comprehensive portfolio of products and services, including FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services.
Platform for liver-humanized mice in gene and cell therapy research
Reagents for liver-related disease and metabolism studies
Services for testing hepatotropic agents in preclinical models
People of Yecuris
Unlock access to complete
Unlock access to complete
Funding Insights of Yecuris
Yecuris has successfully raised a total of $1.25M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $453.28 thousand completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Yecuris
Yecuris has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Janiver Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Animal models for research are supplied with high genetic stability.
|
Locked | Locked | Locked |
Investor details for Yecuris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Yecuris
Investment portfolio details for Yecuris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Yecuris
Detailed financials for Yecuris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Yecuris Comparisons
Peer comparison for Yecuris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Yecuris
Yecuris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
Detailed competitors of Yecuris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Yecuris
Complete news archive for Yecuris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Yecuris
Yecuris was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Yecuris is headquartered in Tualatin, United States. It is registered at Tualatin, Oregon, United States.
Yecuris is a funded company, having raised a total of $1.25M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Yecuris is 26.
Yecuris is developing humanized liver rodent models called FRG KO in various immunocompromised backgrounds. Apart from animal models and cell lines, the company has also developed a high-content screening platform called MetAbArray, which enables the measurement of up to 10 parameters in a single assay. MetAbArray uses HepG2 cells to run the assays. Additionally, the company develops primary human and mouse hepatocytes (Yecuris HepaCur), and the CuRx line of reagents. The company offers research services to clients in the form of technical support for in-vitro and in-vivo research and development as well as consultancy for the design of animal research facilities.
Yecuris's top competitors include Abcam, Sino Biological and Meridian Bioscience.
Yecuris offers FRG Platform, Fresh Hepatocytes, and Viral Hepatitis Research Services.
Yecuris has 2 investors. Key investors include HHS, and Janiver Labs.